N
Google TrendSOCIAL SECURITY 2027 COLA ANNOUNCEMENT (500+) — When will 2027’s Social Security COLA be announced?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:social security 2027 cola announcement500+benfica vs vitória sc200+energy ceasefire200+elliot anderson200+r.c.d. mallorca - u. d. las palmas200+quinyon mitchell2000+tornado north carolina1000+sean young500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "FDA Approves Targeted Com" (30 stories)

Top Headline Story

FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer
Lead StoryTargeted Oncologytech
3d ago

FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPbFRnb0FfTTVTVVJZdFJRWWZZWEtkQW9vN2J2NlJvMi1RLWM3RklINmdKVzh2REJVY01Zb2pLamMzWFl4Q2RiYjJJQmdGSXBDMXBDT21iU2ZqWGhhcUdfQmlkaTN4a1BtUDljbWdJeldXdFN6VkF4NXh2ZEtHQkdzSTJ2NkxkOUw1VUZZcU1KVXdBemlsbTBIMVQyT19wNzRyOEhfMEFB?oc=5" target="_blank">FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+20m ago

social security 2027 cola announcement

When will 2027’s Social Security COLA be announced?

Filter stories
200+30m ago

benfica vs vitória sc

Benfica tem 'roupa nova' para receber o V. Guimarães: o onze provável

Filter stories
200+30m ago

energy ceasefire

Trump announces partial ceasefire in Ukraine war as Zelenskyy says deal is ‘news to me’

Filter stories
200+30m ago

elliot anderson

James McAtee: How Oliver Glasner has transformed Nottingham Forest midfielder from forgotten man to his new Adam Wharton

Filter stories

Search Results for "FDA Approves Targeted Com"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
FDA Approves Lirafugratinib for Treating Cholangiocarcinoma Caused by FGFR2 Mutations
Memorial Sloan Kettering Cancer Centergeneral

FDA Approves Lirafugratinib for Treating Cholangiocarcinoma Caused by FGFR2 Mutations

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPZFBVb24zb1V1T1YzMl82LV9vb2dYYVdRYlo5bXNxQUJOZHJhalhoU0NkVEN3aE1QUFRaYzNJU0VtR09KZzE2SXVKdFNFQjE5WUp0ODl5cGdSRmdZLVFWUnQ2Nkx0d1podWtfSVZtb2lKZ3pucDhXaFU2U0FZRWM3Slh4eEQ1bFVKXzdZN2dCNlJhRWxFV1ZBVFAzUG9RSzNaQ2xXaW1SbTJxSjZ1ZWk0aG5R?oc=5" target="_blank">FDA Approves Lirafugratinib for Treating Cholangiocarcinoma Caused by FGFR2 Mutations</a>  <font color="#6f6f6f">Memorial Sloan Kettering Cancer Center</font>

Read Full StoryMore like this
FDA approves targeted therapy for metastatic pancreatic cancer following UCLA-led study
UCLA Healthgeneral

FDA approves targeted therapy for metastatic pancreatic cancer following UCLA-led study

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQd1JMRmZmYU5wRFdDcENVZ3ZKV0FmY0JzdjExM0ZJY21RcnRMb3dONHEwQjZHN1NCeWVsSDJKU210WGVfNGhpc3MtOVAwNUNQRzd4eUlxSi1pRnVZcFFPcFVscF9BY0JJTzE5QVA2TmdIYjdFVjZPX2M0cVhfeHNCeFZsdkZhVlZNcGZybXoxeDBJMFhmNENXdG9QaFZCSTA?oc=5" target="_blank">FDA approves targeted therapy for metastatic pancreatic cancer following UCLA-led study</a>  <font color="#6f6f6f">UCLA Health</font>

Read Full StoryMore like this
FDA Approves First Targeted Therapy for Dermatomyositis
Muscular Dystrophy Associationgeneral

FDA Approves First Targeted Therapy for Dermatomyositis

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPbW9LV2NwWmZiWDVQeXV6Y0g0Yi1wOW1KUk1kRTduOC1PTjlLRjN5MnNpOE1TYk5OZGJzRUN5Ylh2R1J4V3M0bDNLTFliYk1yMnhhYi1WUzFNYjA3ZFM5UHlzS0VQbEd5eVZITndDamFlZnBfR3F6Z0VjRnZVbFlXV0RMTXlJZWV0NGFBTTR4OUJUVnVv?oc=5" target="_blank">FDA Approves First Targeted Therapy for Dermatomyositis</a>  <font color="#6f6f6f">Muscular Dystrophy Association</font>

Read Full StoryMore like this
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
Targeted Oncologygeneral

FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNWGNJakFnQUZRUGNDY0RkaHVrUWtNRVlaWGRjRkJXQzFPMjBacC03RlljbFZhTmZEY1kya2ZNZkRpMlh6ak12c0J0bWkwcFI4SXZ3X05xME5wZ0M2c0hnZ0JRc2lUZ1ZDQkR6M3lHWk1Dc0s1VlJGUk1kRmo3RDVmN3pnSkhFRkdaSGEzXzJuQVRvOHdVNzlFdEswb3RqZ19vYVE?oc=5" target="_blank">FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease
BioSpacegeneral

FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNX0FEU1FDTktMQ0FrNTBiOURiU1VGQWdLZDMwZ2tjVDZ1a0I2Sm81aFVTS0lmM3preDdrLUpGVS1HQml0NjNHNWpyV083VEk5UkwzaU1yQjgydy04WkV6RmVaU2tNRGVyX29mVHRFMXZFMjVVSG1objNkWWhpWE1iQ0VLVFNFZ1JHQmVtSUhkWUxDNFJMTnREcUQwaVU3dFhiVVZteXNfdzVZYU02Mlhz?oc=5" target="_blank">FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer
Pharmaceutical Executivegeneral

FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOOXpDRVhpVi1IWTF4U3NTdGU2dkJVZndoaEppT2RhWGEtcnk0M3lXdmZGSUg3eFpzeFZYWkZaVjZNVG1JWU5EQUJWVkhab242bUZGRHpFNEFGajdjWTZnZDBDM0xlaUpJdVNaVS1ZdmFpSDNnZy1PM0tOS0RxUWVxU2NSb0lQR2FGdFNsM2dCTTdManc4MVd2T3JhZEtmdVdVNkpqdg?oc=5" target="_blank">FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
FDA Approval Opens New Chapter in Pancreatic Cancer Treatment
University of Miamigeneral

FDA Approval Opens New Chapter in Pancreatic Cancer Treatment

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRDVtNGlYdktlSnJEMWZWdmFGX21NUFBpODZ4aUMtR2tUY0JBaXNENlVzNDBpQThmc0JLMFdMVS1ucmExbUVQV0hnYnhoeUtHMmp1VWdwR2pGN2wzelRGVGwyNnpEM3NteURwNDVzSGozaHFBelRPWENYV0lVeUdMQ05fSU9zUVBi?oc=5" target="_blank">FDA Approval Opens New Chapter in Pancreatic Cancer Treatment</a>  <font color="#6f6f6f">University of Miami</font>

Read Full StoryMore like this
FDA Approves Rasonque, First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer
Cure Todaygeneral

FDA Approves Rasonque, First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNWl9ueXNvUDdzUVU0OUhXNFFZWk0wVE1MSzNGQ2VwRzBkU1NhMlZPMmhwVUtINmRiNDNIVlpsekl5UEJDbmp0NHVGOEZ6UGpsTTNZUDU3VzV3blI4QkMtVVIzTjZYMmF6VWJVUU9qdDZQYVl0bjBsMkxiR21IMlZEZGJUVVlGUDd1Mlp4eHdWcmRQZFc0di1Na09OWE10SkZBVVlrTzhHS3JCRzktTmxlXzR3eS1vTnd4?oc=5" target="_blank">FDA Approves Rasonque, First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
OncLivegeneral

Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNUWVYQ2hvX1NJZTlscnVXMlE0OWRieEdIeUFKQS11bWJKU0txN0Y0b1hsLXVodmxXOEFjbnZMckNOYlJNSEtIc0lLWWNmVUdrV21CdGNCZ2diZ0R5OHVDTlEzWmhYSXJvWFhETktoc1pzMVlGUUdBRVFIMmpsZko2NW1Sd0FoU1VoMUJoYWNnbUVFQjRTRnFibktURmFhZk5UN2NVV3VybWlYcW5SQVRTc3BpVm4?oc=5" target="_blank">Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Apitegromab-mstn, First Muscle-Targeted SMA Therapy
Pharmacy Timesgeneral

FDA Approves Apitegromab-mstn, First Muscle-Targeted SMA Therapy

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQU2UxQzBpdkxKNnU3dXF6N1k1Z1RueVZvdWlrRjh1ZV9tQkFGSmNNY25YRU1URjRZSWNTbE1BUVpSR2dMN0c2UjdXd0FVN0FFQUxmS0xpOGRudnJ1N2RUODNqeVE2ZmtVMUZlbDFMRW1VYnRkRXhSV0xlcjFEcjdmTFRJb196OVBQc2tXaG8xNjY0NG5qano3aExuY0piLVU?oc=5" target="_blank">FDA Approves Apitegromab-mstn, First Muscle-Targeted SMA Therapy</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
The American Journal of Managed Caregeneral

Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPYkJ1bDVGaFU3dG1kclFSSlhqYjAySW1oZ25kelJTVWNJUWJ2UTl3MEd0Zmp2UV9xQm5EajJyb2VRZHR5R0tGXzlZc2FOWUlDR2hhRW1yOHMxRDBxMVNSd3E4NTFBV3hfOVEzTzVMbVF6c3l4TzdzY3oxbllXREptaGx2djI4SVFGdkdJVFktd1hyQzVOTWd1RENB?oc=5" target="_blank">Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
First Therapy to Target Muscle Loss in Spinal Muscular Atrophy Gets FDA Approval
MedPage Todaygeneral

First Therapy to Target Muscle Loss in Spinal Muscular Atrophy Gets FDA Approval

<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE9PNGg2d084c2o5Y0x4N0lhbG13U000T0x3NzlHYXkzb3BqT18yU3I1RGJsazhfQXlEcVYwWk1XY3hzVEZVWjdIUmRteFVPb0lseS1DYlJHMEJqWEl6dk10OXJhSU52dUlySkZkMVUtOA?oc=5" target="_blank">First Therapy to Target Muscle Loss in Spinal Muscular Atrophy Gets FDA Approval</a>  <font color="#6f6f6f">MedPage Today</font>

Read Full StoryMore like this
FDA Approves RASONQUE™ (daraxonrasib)
Pancreatic Cancer Action Networkgeneral

FDA Approves RASONQUE™ (daraxonrasib)

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTFBXVTEyUmZaMXRsRDdaclU0M01vSjVlcTIweWNpcDdoc3Z5YUJGa015UXNIRlBZcGx1SEVITzAtZlhsWGNBcl81WDZwWDljd291VWg5Tkg4S19jNGNFRm1lbzJ6THQtTVdZelVN?oc=5" target="_blank">FDA Approves RASONQUE™ (daraxonrasib)</a>  <font color="#6f6f6f">Pancreatic Cancer Action Network</font>

Read Full StoryMore like this
FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment
Muscular Dystrophy Associationgeneral

FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPa0ZNS01rRUd5UzBEa05lX180dE1rUkdGTlVxT2djanNubzM2dkdZOXBLN0l2MWlaT3Q2M0RIN1hUelhjSEkxVVEwNEF3RDgwcERQZ0ppV0Z4b0g1VlR2Rkh3TEozZ01sX1hENk9PVUZ6UGRBQm9sUm1DX1hxX1J1V1ViRWRKaWlfakZZMEdqT19vVjJSVG1XUXV0c1AxTVdfbXBXR2t0dzhySFBqdTF5MTIwU3hrd2ZXMFFEZXZrYVkwMjVrMlE?oc=5" target="_blank">FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment</a>  <font color="#6f6f6f">Muscular Dystrophy Association</font>

Read Full StoryMore like this
FDA Grants Full Approval to Targeted Therapy for Any Cancer With RET Gene Fusion
Memorial Sloan Kettering Cancer Centergeneral

FDA Grants Full Approval to Targeted Therapy for Any Cancer With RET Gene Fusion

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQWVRjNzEwY1l6RmxXbENjMVZzUzhWWmxsTGhONXlKNHNkd0h4aXV0dU5INmRocGxzSGpHbXhPUml3TmZfWGREZzN4aUF5ajJuVDluS1FvdjFaNXJFQ3RMeVh6a1hjRXp4OTFSaWc4MWlTX3BBbHNPX1R5Ti1WcGl6WjcwQVZzeW9VcEhzUmIzNmNhZkgtSWxFc0tvQlRyeTI2b01NNVFHbmJvOTg?oc=5" target="_blank">FDA Grants Full Approval to Targeted Therapy for Any Cancer With RET Gene Fusion</a>  <font color="#6f6f6f">Memorial Sloan Kettering Cancer Center</font>

Read Full StoryMore like this
FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
Pharmacy Timesgeneral

FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQMmcxNXRTU2s3bVhOc2psejVVTHpEb05TcEdmMG1wOUNaRHRYWk5XNHJBOGN5U0JQNXREU1NmU1Rza3ZaUjh6a3hiLXlubDF4UUY1ZTRZQ1RqMnFQWFM3a2lBUEZlRk41dUpPZm5PWF9nTVVXWmlBcDRxeHI0eEZkMUtzV3d2aDFzNTN2UWY3YmxQbU9tVk1nRjR0dEpkY19tWmpHYjFBUXJsdl83?oc=5" target="_blank">FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
FDA Approves Lirafugratinib for FGFR2-Altered Cholangiocarcinoma
Targeted Oncologygeneral

FDA Approves Lirafugratinib for FGFR2-Altered Cholangiocarcinoma

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQem5OdlE1X2dhWE1KWktVekVPTHFCNUxTcnMxUElHYWY4VXhZRU9ydWpMaXRFU01QMG52dVoxUnN1cHpsMFpzdGRuZHIwZUFfQWpwOGx0bVRncjZRSno2WG9fSnp3bXlrSEhFS3A4S3RZb3QtWnBoTFdGd01Qa0FYZmZpY3VNZTdodENxeGk4REpXYVJ0Q1hBSg?oc=5" target="_blank">FDA Approves Lirafugratinib for FGFR2-Altered Cholangiocarcinoma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA Approves Zanidatamab Combinations for First-Line HER2+ Advanced GEA
Targeted Oncologygeneral

FDA Approves Zanidatamab Combinations for First-Line HER2+ Advanced GEA

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQUG5QUW5YS0ltWUVnR1FYNE1vNHFIUm00Y0NwY09NanpKTjZqWmtmNUtBSExrWGVac0tORURZUUNXVlhXRmNaSGJfQkxSb3JGcFNCd0ZrM3RUc0ctdF9sbUR3b2t0Nk1kdElWRE1Ralg2Q3IxYVd2Z3dqNjRpbTNkRUxBTUV3THdrb3pVOGpvWVViYjdFY290Z21ySngzNVNPeEhGSFRR?oc=5" target="_blank">FDA Approves Zanidatamab Combinations for First-Line HER2+ Advanced GEA</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
Targeted Oncologygeneral

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNQnpqdUJBTnJwcXQ3NHBkZGZrbVJad3E2Z0tJNWgtVGoxaXB1RjF6RVBwWk8zTnh0Y05DSGx0Unk1Z282Y0JyLXdFQkp3cW1jTHd0YzdTOHRQLVpIQ3FJV1VVRzhENEhRV0YxMUMwcmRjaFFCVks5ZnFCeU4tX0dQMFd0ME5wX21mWU5McEstUDIwR25wX2c?oc=5" target="_blank">FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
U.S. FDA grants accelerated approval to Bayer’s targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer
Bayer Globalworld

U.S. FDA grants accelerated approval to Bayer’s targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer

<a href="https://news.google.com/rss/articles/CBMiowJBVV95cUxNLTkyTHRHRk8yaWpudUVFbHR4c1NrMU16SERkc2NCRzhpeDB3M0l5TndCYkIxZEphRGh1QVRQb3ZReWdGUGc5dGphZEt4WUhvTUFfTnEwVi1sR0xzYVpKelJVZS1XNGF3XzdHak5VR0tyeFVVREt3T0V2X0lKZ3ViSGR0SWU5bklLSWFUdzJMZGEyZmVjaElTenIxTnBBYm9ZeXkxWXUyN2dJQS1Xcm9lZlotVjJMNTlYWlNkVnN3ZC1hRVFfY0VYcWVMdm9KUzlpM2dadVBRUEJyN2JkTDJ5Mjl0MkdITW5rR2tTc0NlY2QySWcwaUlhSVBzYXNZOEZFTTRHeE1yYWdpSUNud1BHMU9ncVR6QzNJVTZrMS1iUlczRWs?oc=5" target="_blank">U.S. FDA grants accelerated approval to Bayer’s targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer</a>  <font color="#6f6f6f">Bayer Global</font>

Read Full StoryMore like this
FDA Approves Daraxonrasib for Pancreatic Cancer: What Patients Need To Know
Memorial Sloan Kettering Cancer Centergeneral

FDA Approves Daraxonrasib for Pancreatic Cancer: What Patients Need To Know

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQVW44aHFtT0xweVk4WjItWElHNnA4RU1EbFBUUmZhTGEyakJFRGtpdVlLQmprQVFzeTNlZ2hURzFMV2ZNZjkzd25PRGk3MWdLdXhxaXRWRDdoM2VLTS1VWm1FQjRpSDRPQ2NuM2dkRklaQnY5N1RKQTZtNjF2Y0ZxVXE1T0E4bHZoamZuSmc3dWxhcWVDMlJQMUxoOWZMVXNrUFQ1QXBB?oc=5" target="_blank">FDA Approves Daraxonrasib for Pancreatic Cancer: What Patients Need To Know</a>  <font color="#6f6f6f">Memorial Sloan Kettering Cancer Center</font>

Read Full StoryMore like this
Pasatru Earns FDA Approval to Target Heterotopic Ossification in FOP - MPR
Medical Professionals Referencegeneral

Pasatru Earns FDA Approval to Target Heterotopic Ossification in FOP - MPR

<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTFBFNENLdl9BejF2UHdNNjRNLWxEQkZpdk1RWkRoamliNGhfczhQSG1TVWJ3OXZnWjVycmlTU2ZrajJYYjJoVWlydE5XVDV0ZVBUTGRZdHFOZ05mNDNMWnQ0d2d6eTdIaHVXbk93bHRrZw?oc=5" target="_blank">Pasatru Earns FDA Approval to Target Heterotopic Ossification in FOP - MPR</a>  <font color="#6f6f6f">Medical Professionals Reference</font>

Read Full StoryMore like this
Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
BioSpacegeneral

Scholar Rock secures first FDA approval for muscle-targeting rare disease drug

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRHA0SVBHWXZQd3BuQnBnQ2c2SmxKNWIzMVQ2VG9XNEEyS0ExdXNIM1hKMWR3MnlzSzA5NmU5aTNLeWR1ZUx0VlB3WENzcDg3LUxCLUV1a3g0WjF0TFZRM2JhbzRCWWR4SWgyS3lFREFTNjRQNmphMnBCeDMwVXNTS2FkQkVVdXpCX19kc3JkZ3pSUlk5UDZ2VlJPakdNTm1VY2NvakN3aTVzd1U?oc=5" target="_blank">Scholar Rock secures first FDA approval for muscle-targeting rare disease drug</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
Oncology Nursing Newsgeneral

FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPQWs2S1JYVzh5ZktJUE84Mkk5ZDlaUGRWd1pWNFdCNlRsZDdNeEhNQ2JwTlZBaWZoR3dJTVlscDVsbHZSUjhfZmFTZFNvelE2dm03WnRSajdEb3lnS0tmdkxGU2dQU2RoM3YwSFpBRjdocXd6MWVTb1l3ZWpMZzJTNnZ6RlQxd1QyZVZQeTl6Y2ZwTlF3b3FuNDBURnFoSk9ZQTRKdw?oc=5" target="_blank">FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
Scholar Rock wins FDA approval for first drug to target SMA muscle loss
STATgeneral

Scholar Rock wins FDA approval for first drug to target SMA muscle loss

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNN3doYks2Q0RyZUdibGJRSDlXakMwOWNNU2xoeVdKMDRkY0NIVWctVktUM0pwRzVkLURiYUFTVTFjUFFxcVc4djQxQ1c5NXBvd2hBQk9UVGF0TGJQYXpuZ0VtLXdLWm1qQUIySl9wTDloTUd0bk1vVzN0WUg5V0lDaXVTXzBDU0VZU3BPNm5uYnFCY3lzNUtHWUFyVF93WVRyeEVXZ3FhdTdEc2Q2V1ln?oc=5" target="_blank">Scholar Rock wins FDA approval for first drug to target SMA muscle loss</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
FDA Approves Belzutifan Plus Lenvatinib After Immunotherapy for Advanced Clear Cell Kidney Cancer
SurvivorNetworld

FDA Approves Belzutifan Plus Lenvatinib After Immunotherapy for Advanced Clear Cell Kidney Cancer

<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxOLUFLd2N5OW1LdmZBUmpfZ3k1QVlxaE0wSnNYbFNtaTk3bzFWRDN5aVpOWkFCclJSbDRnblZRSTlGQTJoeUlEVm4xWUp6ZHlOcHJsUnRpbDhxdTBKNlZNWWpBSl9MSXJuemliRzgwTmVabkxhTkVISUl2czlVS1QybkVKcGcyMVVrdlFDLVNhMC1zTDJXSDQ4MnZSRXB3R2dPVHBVUm00SmgzTFZOMFRuRnM0VUJ3YWJnaV9zY0MwSlU1ZW45M2RQdGlMeWI0azR1czRMeHNZbTVVM1dOVVdFdE1nZGlNTjlwZlJORi1MUC1iY2ZWcE5TN3YtSEdMSGR1RmpmVHF3?oc=5" target="_blank">FDA Approves Belzutifan Plus Lenvatinib After Immunotherapy for Advanced Clear Cell Kidney Cancer</a>  <font color="#6f6f6f">SurvivorNet</font>

Read Full StoryMore like this
FDA Approves SimpleScreen Blood Test for CRC Screening
Targeted Oncologygeneral

FDA Approves SimpleScreen Blood Test for CRC Screening

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNY3V2cTVrZzJRaWNJamEtUDlKeWs3V0J2SmpSYXdlQmlPX3BycUJtWDhTcFpyZ3o0M1cteG9xVWZNVE9fOFBPR191cDFubXdJcklZX1hnUUVQci1aRG5xYzZKMUpRNjZfdlpxU0VZaEVzNnFxRUMwdDl6N1REODdiZWdiV1lVVl9WWHRkNF9ud3o?oc=5" target="_blank">FDA Approves SimpleScreen Blood Test for CRC Screening</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA Approves Apitegromab for Spinal Muscular Atrophy
NeurologyLivegeneral

FDA Approves Apitegromab for Spinal Muscular Atrophy

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOT01OM1ZFMUdMNW9DdU1JbkkzMnNKYWVhYUZyLVRhYXVpRnpMeXZXZHJTZ3RDNzRzdTdOYjdmMkJCVC1QWE9GcEM4cTZ0QVNFYl92aFZBMG14SE56S3IwN2M4VkktbjNLN19DTEw5T0FOUEl0dGlHUUNEcFlrQ0VLa2V0YUNnYmZMXzZF?oc=5" target="_blank">FDA Approves Apitegromab for Spinal Muscular Atrophy</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
FDA Approves Brepocitinib for Dermatomyositis
Dermatology Timesgeneral

FDA Approves Brepocitinib for Dermatomyositis

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOY3dBN2lSdHdibmtNWEM3aTVxRGt0ME83ZlhpYUk1V1V2c0Nrb3BLbjZPeURfNV9mTmFELUs2Y3g0SGlld0VjWTA0cFRWLXFoWWtadWxOTDJBZWc5V0p0bjNCNmVuaEhnc3NsejNabDV0RE13eEQ5VkR5eldqZWdSUjRIVGM1VzRlQnZR?oc=5" target="_blank">FDA Approves Brepocitinib for Dermatomyositis</a>  <font color="#6f6f6f">Dermatology Times</font>

Read Full StoryMore like this
"FDA Approves Targeted Com" — Live Google News Trends & Headlines